↓ Skip to main content

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.

Overview of attention for article published in Journal of Clinical Oncology, February 1999
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

policy
2 policy sources
patent
1 patent
guideline
1 clinical guideline source

Readers on

mendeley
105 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.
Published in
Journal of Clinical Oncology, February 1999
DOI 10.1200/jco.1999.17.2.485
Pubmed ID
Authors

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 105 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
United Kingdom 1 <1%
Unknown 104 99%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Student > Ph. D. Student 15 14%
Other 13 12%
Researcher 13 12%
Student > Bachelor 8 8%
Student > Master 7 7%
Other 18 17%
Unknown 31 30%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 41 39%
Agricultural and Biological Sciences 7 7%
Biochemistry, Genetics and Molecular Biology 6 6%
Nursing and Health Professions 4 4%
Business, Management and Accounting 2 2%
Other 13 12%
Unknown 32 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 September 2014.
All research outputs
#3,805,579
of 34,526,284 outputs
Outputs from Journal of Clinical Oncology
#10,020
of 32,752 outputs
Outputs of similar age
#6,413
of 144,510 outputs
Outputs of similar age from Journal of Clinical Oncology
#18
of 99 outputs
Altmetric has tracked 34,526,284 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 32,752 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.6. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 144,510 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 99 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.